LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

• Main Authors: Dongcheng Liu (Author), Hongguang Liu (Author), Jiadi Gan (Author), Shinuan Zeng (Author), Fuhua Zhong (Author), Bin Zhang (Author), Zhe Zhang (Author), Siyu Zhang (Author), Lu Jiang (Author), Guangsuo Wang (Author), Yixin Chen (Author), Feng-Ming Spring Kong (Author), Wenfeng Fang (Author), Lingwei Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Non-small cell lung carcinoma (NSCLC) patients who initially received tyrosine kinase inhibitor (TKI) therapy often acquired resistance via multiple complex mechanisms. The amplification of FGF3/4/19/CCND1 on chromosome 11q13 was found in many cancers with TKI resistance. However, the role of these...